Carcinoid tumor of thymus
ICD-10 C37 · ICD-11 2C27.1

Treatment of Carcinoid Tumor of Thymus in Carcinoid Syndrome

This protocol addresses the management of carcinoid tumor of the thymus in patients presenting with carcinoid syndrome — a specific clinical sub-population requiring targeted symptomatic treatment.

Clinical Scenario
Carcinoid Syndrome

The presence of carcinoid syndrome defines the treatment context here. Managing carcinoid syndrome symptoms is a central clinical priority alongside the underlying thymic tumor.

Treatment Goals

The primary objective is significant improvement of carcinoid syndrome. The full protocol outlines the structured pathway for achieving this clinical endpoint.

Treatment Approach (partial overview)

First-line symptomatic management involves a class of agents targeting somatostatin receptors, with a specific formulation approach adapted for the perioperative setting.

Full regimen details, sequencing, and clinical decision points are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2021.01.003

  • We recommend long-acting SSAs as first-line symptomatic treatment of CS [V, B].
  • SSAs are recommended as first-line therapy for CS [V, B].
  • Short-acting SSAs given intravenously are recommended in perioperative treatment [IV, A].
View source ↗